Search research articles
Contact Us
Filters
Showing results (251-260 of 418) with videos related to
Page
of 42
Sort By:
Cardio-Oncology (London, England)
|
November 24, 2022
The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunction
Maria Sol Andres, Sivatharshini Ramalingam, Stuart D Rosen, et al.
The Lancet. Oncology
|
October 21, 2015
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J Motzer, Thomas E Hutson, Hilary Glen, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
August 14, 2023
Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: insights from the TRACERx Renal study
Matthew R Orton, Evan Hann, Simon J Doran, et al.
The Journal of Pathology
|
February 25, 2012
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target
Marco Gerlinger, Claudio R Santos, Bradley Spencer-Dene, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2017
Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
Matthew J Wongchenko, Grant A McArthur, Brigitte Dréno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Nature Communications
|
July 15, 2024
Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma
Richard Culliford, Samuel E D Lawrence, Charlie Mills, et al.
Human Molecular Genetics
|
April 20, 2022
Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases
Bryndis Yngvadottir, Avgi Andreou, Laia Bassaganyas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma
Meredith M Regan, Lillian Werner, Sumati Rao, et al.
Journal of Translational Medicine
|
June 26, 2017
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
Luis de la Cruz-Merino, Lorenza Di Guardo, Jean-Jacques Grob, et al.
Page
of 42
Search research articles
Search
Showing results (251-260 of 418) with videos related to
Sort By:
Page
of 42
Cardio-Oncology (London, England)
|
November 24, 2022
The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunction
Maria Sol Andres, Sivatharshini Ramalingam, Stuart D Rosen, et al.
The Lancet. Oncology
|
October 21, 2015
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J Motzer, Thomas E Hutson, Hilary Glen, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
August 14, 2023
Interpretability of radiomics models is improved when using feature group selection strategies for predicting molecular and clinical targets in clear-cell renal cell carcinoma: insights from the TRACERx Renal study
Matthew R Orton, Evan Hann, Simon J Doran, et al.
The Journal of Pathology
|
February 25, 2012
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target
Marco Gerlinger, Claudio R Santos, Bradley Spencer-Dene, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2017
Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
Matthew J Wongchenko, Grant A McArthur, Brigitte Dréno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, et al.
Nature Communications
|
July 15, 2024
Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma
Richard Culliford, Samuel E D Lawrence, Charlie Mills, et al.
Human Molecular Genetics
|
April 20, 2022
Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases
Bryndis Yngvadottir, Avgi Andreou, Laia Bassaganyas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma
Meredith M Regan, Lillian Werner, Sumati Rao, et al.
Journal of Translational Medicine
|
June 26, 2017
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
Luis de la Cruz-Merino, Lorenza Di Guardo, Jean-Jacques Grob, et al.
Page
of 42